Fibre Grain Herb Trial in Type 2 Diabetes (FIGHT)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Dietary, Herbal
Positive Control
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes medically diagnosed for at least 6-months prior to randomization
- HbA1c (glycated hemoglobin) between 6.3% and 8.5% at screening
- BMI < 35 kg/m2
Exclusion Criteria:
- Insulin therapy
- Blood pressure ≥ 160/100 mmHg
- Serum triglyceride >4.5mmol/L
- History of major cardiovascular events (stroke or myocardial infarction)
- Gastrointestinal, liver or kidney disease
- Consumption of alcohol >2 drinks/day
- Current tobacco smokers
- Taking the following medications: herbs or supplements that may affect primary or secondary outcomes, monoamine oxidase inhibitors (MAOIs) antidepressants and/or anticoagulant therapy
- Women with hormone sensitive tumors/conditions
Sites / Locations
- St. Michael's Hopsital
- Clinical Centre Vuk Vrhovac, Merkur Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dietary, Herbal
Positive Control
Arm Description
Outcomes
Primary Outcome Measures
Change in HbA1c
Assessed via laboratory analysis
Secondary Outcome Measures
Change in LDL-C
Assessed via laboratory analysis
Change in 24h ambulatory systolic blood pressure
Assessed via analysis
Full Information
NCT ID
NCT02553382
First Posted
July 30, 2015
Last Updated
May 21, 2020
Sponsor
Unity Health Toronto
Collaborators
Canadian Diabetes Association
1. Study Identification
Unique Protocol Identification Number
NCT02553382
Brief Title
Fibre Grain Herb Trial in Type 2 Diabetes
Acronym
FIGHT
Official Title
Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
April 2018 (Actual)
Study Completion Date
April 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto
Collaborators
Canadian Diabetes Association
4. Oversight
5. Study Description
Brief Summary
Despite the availability of multiple medications for the treatment of Type 2 diabetes, patients often continue to have difficulty attaining blood glucose targets and managing cardiovascular disease risk factors. Recent trends in non-pharmacological therapy have created a growing public interest in dietary supplements.
Research by this group and others support the benefits of whole grains, viscous dietary fibre and ginseng in the management of diabetes. The current study investigates whether the co-administration of a viscous dietary fibre blend, Salba (a grain rich in omega-3 fatty acids), and 2 varieties of ginseng roots will further improve blood sugar control and cardiovascular disease risk outcomes in individuals with Type 2 diabetes already receiving conventional treatments.
Patients with Type 2 diabetes receiving the recommended intervention in accordance with the Canadian Diabetes Association guidelines will be enrolled in a 6-month clinical study. Half of the participants will be randomly assigned to a 4-component intervention that comprises the co-administration of these four dietary/herbal supplements in addition to their usual treatment regimen; the other half will continue their usual treatment regimen in addition to taking high-oat fiber and wheat bran supplements.
The investigators hypothesize that an intensified, multi-targeted intervention with the addition of these dietary and herb components will further improve long-term blood glucose control and cardiovascular disease risk factors beyond conventional therapy. If this combination of viscous fiber, Salba and ginseng is shown to be beneficial, these remedies could complement current conventional therapy for Type 2 diabetes with the goal to further improve health outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
104 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dietary, Herbal
Arm Type
Experimental
Arm Title
Positive Control
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Dietary, Herbal
Intervention Description
Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
Intervention Type
Dietary Supplement
Intervention Name(s)
Positive Control
Intervention Description
Oat bran blend and wheat bran capsules
Primary Outcome Measure Information:
Title
Change in HbA1c
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Secondary Outcome Measure Information:
Title
Change in LDL-C
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in 24h ambulatory systolic blood pressure
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Other Pre-specified Outcome Measures:
Title
Change in fasting glucose
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in fasting insulin
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in HOMA-IR
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in total cholesterol
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in triglycerides
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in HDL-C
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in total cholesterol:HDL-C
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in Non-HDL-C
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in Apo-B
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
Title
Change in 24h diastolic BP
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in office systolic BP
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in office diastolic BP
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in central systolic BP
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in central diastolic BP
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in Augmentation index at heart rate 75 bpm
Description
Assessed via analysis
Time Frame
Baseline to 24 weeks
Title
Change in Hs-CRP
Description
Assessed via laboratory analysis
Time Frame
Baseline to 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes medically diagnosed for at least 6-months prior to randomization
HbA1c (glycated hemoglobin) between 6.3% and 8.5% at screening
BMI < 35 kg/m2
Exclusion Criteria:
Insulin therapy
Blood pressure ≥ 160/100 mmHg
Serum triglyceride >4.5mmol/L
History of major cardiovascular events (stroke or myocardial infarction)
Gastrointestinal, liver or kidney disease
Consumption of alcohol >2 drinks/day
Current tobacco smokers
Taking the following medications: herbs or supplements that may affect primary or secondary outcomes, monoamine oxidase inhibitors (MAOIs) antidepressants and/or anticoagulant therapy
Women with hormone sensitive tumors/conditions
Facility Information:
Facility Name
St. Michael's Hopsital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1M4
Country
Canada
Facility Name
Clinical Centre Vuk Vrhovac, Merkur Hospital
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
12. IPD Sharing Statement
Citations:
PubMed Identifier
33486572
Citation
Zurbau A, Smircic Duvnjak L, Magas S, Jovanovski E, Miocic J, Jenkins AL, Jenkins DJA, Josse RG, Leiter LA, Sievenpiper JL, Vuksan V. Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial. Eur J Nutr. 2021 Sep;60(6):3071-3083. doi: 10.1007/s00394-020-02434-7. Epub 2021 Jan 24.
Results Reference
derived
Learn more about this trial
Fibre Grain Herb Trial in Type 2 Diabetes
We'll reach out to this number within 24 hrs